Short Communication
HCV elimination and the opioid crisis – joint epidemics, joint solutions: results of a pilot program
Published Online:4 Mar 2019https://doi.org/10.2217/fvl-2018-0206
Abstract
Aim: People who use drugs in Canada are disproportionately affected by both the HCV and opioid overdose epidemics. It is feasible to envision a solution to address both issues simultaneously. Methodology: A retrospective chart review of HCV-infected patients with a history of drug use was conducted. All patients enrolled at our center have access to multidisciplinary care to address medical, social, psychiatric and addictions-related needs in an integrated manner. Results: Since 2014, 337 individuals have initiated HCV treatment, in whom 30 medically significant overdoses have occurred, including three deaths. Conclusion: The model we have developed could be an ideal approach to address HCV, as well as respond to the opioid crisis, in a high-risk population.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1 . Hepatitis C in Canada and the importance of risk-based screening. Can. Comm. Dis. Rep. 42, 57–62 (2016).
- 2 . The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr. Opin. HIV AIDS 10, 374–380 (2015). •• Gave a detailed overview of the HCV epidemic in key populations, as well as discussing the concurrent harm reduction and treatment scale-up necessary to achieve HCV elimination goals.
- 3 WHO. Global health sector strategy on viral hepatitis, 2016–2021: towards ending viral hepatitis (2016). http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf.
- 4 The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin. Liver Dis. 38, 181–192 (2018). •• Described the concept of microelimination, as well as key case studies of the concept in action.
- 5 British Columbia Coroner's Service. Illicit drug overdose deaths in BC January 1, 2008 – September 30, 2018 (2018). www2.gov.bc.ca/assets/gov/birth-adoption-death-marriage-and-divorce/deaths/coroners-service/statistical/illicit-drug.pdf.
- 6 . Expanding supervised injection facilities across Canada: lessons from the Vancouver experience. C. J. Public Health 109(2), 227–230 (2018).
- 7 . Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm. Reduct. J. 15, 46 (2018).
- 8 . Why the FUSS (fentanyl urine screen study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm. Reduct. J. 12, 54 (2018). • This survey demonstrated that 29% of drugs tested at 17 harm reduction sites contained fentanyl, of which 73% were unknowingly and unintentionally purchased by the consumer.
- 9 . Research on a vulnerable neighborhood – the Vancouver Downtown Eastside from 2001 to 2011. J. Urban Health 90(3), 559–573 (2013). • This review described the history and development of the current conditions of the Downtown Eastside of Vancouver, giving context to the current opioid overdose epidemic, as well as detailing the themes and outcomes of research studies conducted in this neighborhood and outlining key gaps in the literature.
- 10 Diagnosis and treatment of hepatitis C virus infection: a tool for engagement with people who inject drugs in Vancouver's Downtown Eastside. Can. Liv. J. 1(2), 4–13 (2018).
- 11 Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 326(7396), 959–960 (2003).
- 12 . Healthcare utilisation and disclosure of injecting drug use among clients of Australia's needle and syringe programs. Aust. NZ J. Publ. Heal. 37(2), 148–154 (2013).
- 13 . Chronic illicit drug use, health services utilization and the cost of medical care. Soc. Sci. Med. 50(12), 1703–1713 (2000).
- 14 . Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. Am. Behav. Sci. 34(4-5), 727–746 (1999). • Analyzed the healthcare utilization of 1330 individuals, demonstrating that drug was independently associated with increased need for healthcare, and also decreased likelihood of receiving healthcare.
- 15 . Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depen. 131, 23–35 (2013). • This review demonstrated that healthcare professionals have generally negative views and lack empathy toward PWUD, which lead to poor treatment outcomes for this population.
- 16 . Successful treatment of hepatitis C in a dedicated GP practice for the homeless using a multidisciplinary approach. Presented at: 7th International Symposium on Hepatitis Care in Substance Users. Cascais, Portugal, 19–21 September 2018.
